Abstract
A set of fluorophenoxyanilides, designed to be simplified analogues of previously reported ω-conotoxin GVIA mimetics, were prepared and tested for N-type calcium channel inhibition in a SH-SY5Y neuroblastoma FLIPR assay. N-type or Cav2.2 channel is a validated target for the treatment of refractory chronic pain. Despite being significantly less complex than the originally designed mimetics, up to a seven-fold improvement in activity was observed.
| Original language | English |
|---|---|
| Pages (from-to) | 2030-2045 |
| Number of pages | 16 |
| Journal | Marine Drugs |
| Volume | 13 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Apr 2015 |
Keywords
- Cav2.2
- Channel blocker
- FLIPR
- N-type calcium channel
- Pain